{
    "pmcid": "8726723",
    "qa_pairs": {
        "What advantage do nanobodies offer for therapeutic applications against COVID-19?": [
            "Small size, stability, and ease of production",
            "Ability to bind multiple epitopes simultaneously",
            "Higher affinity than traditional antibodies",
            "Resistance to degradation in the bloodstream"
        ],
        "What is the primary target for neutralizing antibodies identified in the study on the SARS-CoV-2 spike protein?": [
            "The receptor-binding domain (RBD) of the S1 subunit",
            "The S2 subunit facilitating membrane fusion",
            "The entire spike protein trimer",
            "The N-terminal domain (NTD) of the spike protein"
        ],
        "What was a key finding regarding the resistance of some antibodies to SARS-CoV-2 variants?": [
            "They retained neutralizing activity against variants with spike protein mutations",
            "They lost all neutralizing activity against new variants",
            "They were only effective against the original Wuhan strain",
            "They required modification to maintain efficacy against variants"
        ],
        "What was demonstrated by combining antibodies with distinct epitopes in the study?": [
            "Additive neutralization effects",
            "Increased risk of viral escape",
            "Reduced therapeutic efficacy",
            "Decreased antibody stability"
        ],
        "Which method was used to rapidly identify antibodies with high affinity and specificity for the SARS-CoV-2 S1 subunit?": [
            "Synthetic phage libraries with shuffled CDR loops",
            "CRISPR-Cas9 gene editing",
            "Monoclonal antibody production from convalescent plasma",
            "In silico modeling and simulation"
        ]
    }
}